1. Protein Tyrosine Kinase/RTK Metabolic Enzyme/Protease Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR MAPK/ERK Pathway Apoptosis
  2. PDGFR Carbonic Anhydrase STAT Akt ERK Apoptosis Caspase
  3. PDGFRA/CAIX/XII-IN-1

PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA, a Ki of 93.3 nM against CA IX, and a Ki of 80.0 nM against CA XII. PDGFRA/CAIX/XII-IN-1 binds to the ATP-binding pocket of PDGFRA and blocks the downstream STAT3, AKT and ERK1/2 signaling pathways. PDGFRA/CAIX/XII-IN-1 induces G0/G1 cell cycle arrest and endogenous apoptosis (Apoptosis), including cleavage of PARP-1, caspase-9 and caspase-3, activation of caspase 3/7, and down-regulation of Mcl-1. PDGFRA/CAIX/XII-IN-1 exhibits antiproliferative activity in eosinophilic leukemia cells. PDGFRA/CAIX/XII-IN-1 can be used for the research of leukemia.

For research use only. We do not sell to patients.

PDGFRA/CAIX/XII-IN-1

PDGFRA/CAIX/XII-IN-1 Chemical Structure

Size Price Stock
5 mg Ask For Quote & Lead Time
10 mg Ask For Quote & Lead Time
25 mg Ask For Quote & Lead Time
50 mg Ask For Quote & Lead Time
100 mg Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All PDGFR Isoform Specific Products:

View All Carbonic Anhydrase Isoform Specific Products:

View All STAT Isoform Specific Products:

View All Akt Isoform Specific Products:

View All ERK Isoform Specific Products:

View All Caspase Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA, a Ki of 93.3 nM against CA IX, and a Ki of 80.0 nM against CA XII. PDGFRA/CAIX/XII-IN-1 binds to the ATP-binding pocket of PDGFRA and blocks the downstream STAT3, AKT and ERK1/2 signaling pathways. PDGFRA/CAIX/XII-IN-1 induces G0/G1 cell cycle arrest and endogenous apoptosis (Apoptosis), including cleavage of PARP-1, caspase-9 and caspase-3, activation of caspase 3/7, and down-regulation of Mcl-1. PDGFRA/CAIX/XII-IN-1 exhibits antiproliferative activity in eosinophilic leukemia cells. PDGFRA/CAIX/XII-IN-1 can be used for the research of leukemia[1].

IC50 & Target[1]

CA IX

93.3 nM (Ki)

CA XII

80 nM (Ki)

STAT3

 

ERK1

 

ERK2

 

Caspase-9

 

Caspase 3

 

In Vitro

PDGFRA/CAIX/XII-IN-1 (Compound 9d) potently inhibits recombinant PDGFRA protein, with an IC50 of 20 nM[1].
PDGFRA/CAIX/XII-IN-1 (1 μM) exerts targeted inhibitory effects on specific RTK subfamilies, and exhibits potent activity against PDGFRα and closely related class III RTKs[1].
PDGFRA/CAIX/XII-IN-1 inhibits recombinant human cancer-associated CA IX (Ki = 93.3 nM) and CA XII (Ki = 80.0 nM) with moderate potency, while exhibiting only weak activity against normal CA I/II isoforms[1].
PDGFRA/CAIX/XII-IN-1 (72 h) potently inhibits the proliferation of FIP1L1-PDGFRA-driven EOL-1 eosinophilic leukemia cells (GI50 = 2 nM), also exhibits significant cytotoxicity against MV4-11 cells (GI50 = 0.263 μM), and shows weak cytotoxicity against Kasumi-1 and RS4-11 cells with GI50 values of 2.081 μM and 4.599 μM, respectively[1].
PDGFRA/CAIX/XII-IN-1 (0-2500 nM; 1 h) dose-dependently inhibits the phosphorylation of FIP1L1-PDGFRA and its downstream STAT3, AKT and ERK1/2 signaling pathways in EOL-1 cells; after treatment at a concentration of 100 nM for 1 h, the inhibitory effect on PDGFRA is nearly complete[1].
PDGFRA/CAIX/XII-IN-1 (0-2500 nM; 24 h) induces apoptosis in EOL-1 eosinophilic leukemia cells by activating the intrinsic apoptotic pathway. The effect is detectable at a concentration of 0.8 nM, and the pathway is potently activated at subnanomolar concentrations, while no pro-apoptotic effect is observed on THP-1 cells[1].
PDGFRA/CAIX/XII-IN-1 (0.16-100 nM; 24 h) induces dose-dependent G0/G1 cell cycle arrest in EOL-1 eosinophilic leukemia cells, with a significant arrest effect observed at 0.8 nM; additionally, after 24 h of treatment, concentrations of 4 nM and above induce apoptotic cell death (characterized by a sub-G1 cell population)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: EOL-1 cells
Concentration: 0, 4, 20, 100, 500, 2500 nM
Incubation Time: 1 h
Result: Induced a dose-dependent inhibition of FIP1L1-PDGFRA phosphorylation (p-PDGFRA/B Y849/857), with substantial reduction at 20 nM and near-complete dephosphorylation at 100 nM.
Reduced phosphorylation of downstream signaling molecules STAT3 (p-STAT3 Y705) from 20 nM upward, AKT (p-AKT S473) with substantial inhibition at 100 nM and above, and ERK1/2 (p-ERK1/2 T202/Y204) with strong inhibition from 100 nM.
Maintained unchanged total protein levels of PDGFRA, STAT3, AKT, and ERK1/2.

Apoptosis Analysis[1]

Cell Line: EOL-1 cells, THP-1 cells
Concentration: 0.032, 0.16, 0.8, 4, 20, 100, 500 2500 nM (caspase 3/7 activity, Western blot); 0.16, 4, 100 nM (Annexin V/PI staining)
Incubation Time: 24 h
Result: In EOL-1 cells: induced dose-dependent cleavage of PARP-1 (detectable at 0.8 nM, accumulating at 4 nM and higher), reduced antiapoptotic Mcl-1 expression (substantial reduction at 4 nM, near-complete depletion at 20 nM), activated caspase 9 (cleavage detected at 4 nM and higher) and caspase 3 (cleavage detected at 4 nM and higher).
Caused a robust, dose-dependent increase in caspase 3/7 activity (significant activation at 0.032 nM, ~7-fold increase at 0.8 nM).
Induced a concentration-dependent shift from viable cells to early and late apoptotic populations via Annexin V/PI staining.
In THP-1 cells: showed no significant signs of apoptosis or caspase 3/7 activation at tested concentrations.

Cell Cycle Analysis[1]

Cell Line: EOL-1 cells
Concentration: 0.16, 0.8, 4, 20, 100 nM
Incubation Time: 24 h
Result: Caused a dose-dependent accumulation of cells in the G0/G1 phase, accompanied by a decrease in S and G2/M populations.
Induced modest G0/G1 arrest at 0.16 nM, significant arrest at 0.8 nM and higher.
Triggered a sub-G1 apoptotic population from 4 nM onward, which expanded markedly at 20 and 100 nM.
Molecular Weight

507.56

Formula

C25H25N5O5S

SMILES

O=C(NC1=CC(S(=O)(N)=O)=C(C=C1)C)NC2=CC=C(C=C2)NC3=C4C=C(C(OC)=CC4=NC=C3)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDGFRA/CAIX/XII-IN-1
Cat. No.:
HY-181587
Quantity:
MCE Japan Authorized Agent: